PALBI与ALBI评分在肝细胞癌患者TACE术后并发症预测应用的研究进展

Research Progress on the Application of PALBI and ALBI Scores in Predicting Postoperative Complications Following TACE in Hepatocellular Carcinoma Patients

摘要: 肝细胞癌(HCC)为我国高发恶性肿瘤，经动脉化疗栓塞(TACE)为不可切除或中晚期患者的重要局部治疗手段，但术后并发症尤其肝功能衰竭、感染及出血显著影响预后。传统Child-Pugh级受主观因素限制，ALBI (albumin-bilirubin)评分与PALBI (platelet-ALBI)评分基于客观生化指标，为术前肝功能与门脉高压的量化评估提供新工具，可能更全面地评估肝脏储备与并发症风险。本文综述近年来关于ALBI与PALBI评分在HCC接受TACE患者术后并发症预测领域的研究进展，比较两者在不同研究队列中的预测性能、敏感性与特异性，并分析影响其预测能力的关键因素，有助于优化术前筛选、个体化治疗及围术期管理，降低并发症发生，改善生存结局。

Abstract: Hepatocellular carcinoma (HCC) is a high incidence malignant tumor in China. Transarterial chemoembolization (TACE) is an important local treatment for unresectable or advanced patients, but postoperative complications, especially liver failure, infection and bleeding, significantly affect the prognosis. The traditional child Pugh scale is limited by subjective factors. The ALBL (Albumin-Bilirubin) score and PALBI (Platelet-ALBI) score are based on objective biochemical markers, which provide a new tool for the quantitative assessment of preoperative liver function and portal hypertension. These scores may provide a more comprehensively assess the risk of liver reserve and complications. This article reviews the research progress of ALBI and PALBI score in predicting postoperative complications of HCC patients receiving TACE in recent years, compares their predictive performance, sensitivity and specificity in different research cohorts, and analyzes the key factors affecting their predictive ability, which is helpful to optimize preoperative screening, individualized treatment and perioperative management, reduce complications, and improve survival outcomes.